Company secures operations of its content moderation watchdog with undisclosed additional funding amid role uncertainty. Meta has committed additional funding to extend its Oversight Board’s operations through 2028. The move follows a prior 2024 agreement guaranteeing at l
The nationwide gold rush for electrical power is lifting solar energy stocks after several lean years for the industry. As AI hyperscalers hunt for any and all sources of power for their data centers, they've also turned to solar energy companies Amid this resurgenc
The nationwide gold rush for electrical power is lifting solar energy stocks after several lean years for the industry. As AI hyperscalers hunt for any and all sources of power for their data centers, they've also turned to solar energy companies Amid this resurgenc
VTV rises 11% year-to-date, surpassing VUG’s 9.4% return amid higher Treasury yields and shifting market breadth. Vanguard Value ETF (VTV) has gained 11% year-to-date, outperforming the Vanguard Growth ETF (VUG), which returned 9.4%. The shift follows rising Treasury yield
VTV rises 11% year-to-date, surpassing VUG’s 9.4% return amid higher Treasury yields and shifting market breadth. Vanguard Value ETF (VTV) has gained 11% year-to-date, outperforming the Vanguard Growth ETF (VUG), which returned 9.4%. The shift follows rising Treasury yield
Novo Nordisk’s new Wegovy pill shows stronger efficacy than Eli Lilly’s GLP-1 pill, challenging Lilly’s dominance in weight-loss drugs. Novo Nordisk’s recently launched Wegovy pill is gaining traction as a more effective alternative to Eli Lilly’s GLP-1 pill, despite Lilly
Novo Nordisk’s new Wegovy pill shows stronger efficacy than Eli Lilly’s GLP-1 pill, challenging Lilly’s dominance in weight-loss drugs. Novo Nordisk’s recently launched Wegovy pill is gaining traction as a more effective alternative to Eli Lilly’s GLP-1 pill, despite Lilly
Kohl’s first-quarter results exceeded estimates, with revenue of $3 billion and a smaller-than-feared comparable sales decline. Kohl’s Corporation reported a first-quarter diluted loss of $0.13 per share, beating Wall Street’s forecast of a $0.21 loss. Revenue reached $3 b
Kohl’s first-quarter results exceeded estimates, with revenue of $3 billion and a smaller-than-feared comparable sales decline. Kohl’s Corporation reported a first-quarter diluted loss of $0.13 per share, beating Wall Street’s forecast of a $0.21 loss. Revenue reached $3 b
Conavi Medical Corp. press release (CNVI:CA): Q2 - Revenue of C$0.1M (flat Y/Y). - Net loss for Fiscal Q2 2026 was C$4.8 million, compared to a net loss of C$3.1 million in the prior-year period. - Cash and cash equivalents were C$4.5 million as of March 31, 2026, compared to...<
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.